Camp4 Therapeutics (CAMP) Net Equity Issued and Repurchased (2023 - 2024)

Camp4 Therapeutics (CAMP) posted Net Equity Issued and Repurchased of $76.3 million for Q4 2024, up 246093.55% sequentially from $31000.0 in Q3 2024, and up 636100.0% YoY from N/an in Q1 2024.

Camp4 Therapeutics (CAMP) Net Equity Issued and Repurchased (2023 - 2024) Analysis & Trends

Camp4 Therapeutics has reported Net Equity Issued and Repurchased for 2 years, with the latest figure at $76.3 million in Q4 2024.

  • Quarterly Net Equity Issued and Repurchased rose 636100.0% year-over-year to $76.3 million in Q4 2024, while the trailing twelve-month figure through Jun 2025 was $76.4 million (changed N/A YoY) and the FY2025 annual result came in at $57.5 million, down 24.67% from the prior year.
  • Net Equity Issued and Repurchased improved to $76.3 million in Q4 2024 per CAMP's latest filing, from $31000.0 in the prior quarter.
  • Over five years, Net Equity Issued and Repurchased peaked at $76.3 million in Q4 2024 and troughed at -$12000.0 in Q4 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 49.20 Mn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - 141.90 Mn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn -
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -
10 Camp4 Therapeutics 282.48 Mn 282.48 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2024 76.32 Mn
Dec 31, 2024 76.32 Mn
Sep 30, 2024 31,000.00
Sep 30, 2024 31,000.00
Mar 31, 2024 2,000.00
Mar 31, 2024 2,000.00
Dec 31, 2023 -12,000.00
Dec 31, 2023 -12,000.00